eCite Digital Repository
Observational study of brain atrophy and cognitive decline comparing a sample of community-dwelling people taking angiotensin converting enzyme inhibitors and angiotensin receptor blockers over time
Citation
Moran, C and Xie, K and Poh, S and Chew, S and Beare, R and Wang, W and Callisaya, M and Srikanth, V, Observational study of brain atrophy and cognitive decline comparing a sample of community-dwelling people taking angiotensin converting enzyme inhibitors and angiotensin receptor blockers over time, Journal of Alzheimer's Disease, 68, (4) pp. 1479-1488. ISSN 1387-2877 (2019) [Refereed Article]
![]() | PDF (Final author version) 302Kb |
Copyright Statement
Copyright 2019 IOS Press and the authors. The final publication is available at IOS Press through http://dx.doi.org/10.3233/JAD-180943
Abstract
Objective: To compare brain atrophy and cognitive decline between people treated with ACEi or ARB.
Methods: Participants aged 55-90 years without dementia had brain magnetic resonance imaging and neuropsychological assessments performed at 3 time points. The sample was enriched with people with type 2 diabetes (T2D). Multivariable mixed models were used to examine longitudinal associations of antihypertensive medication class with change in cognition and total brain volume.
Results: Of 565 people with longitudinal data, there were 163 on ACEi (mean age 69.9 years, T2D:64% with) and 125 on ARB (mean age 69.6 years, T2D:62%) at baseline. The baseline characteristics of those taking either an ACEi or ARB were similar with regards to age, sex, blood pressure control, and vascular risk factors. The mean duration of follow up was 3.2 years. The baseline association of ACEi and ARB use with total brain volume was similar in both groups. However, those taking an ARB had a slower rate of brain atrophy than those taking an ACEi (p = 0.031). Neither ACEi nor ARB use was associated with baseline cognitive function or cognitive decline.
Conclusions: These results support the theory that ARB may be preferable to ACEi to reduce brain atrophy. The mechanisms underlying this differential association warrant further investigation.
Item Details
Item Type: | Refereed Article |
---|---|
Keywords: | angiotensin-converting enzyme inhibitors, antihypertensive agents, blood pressure, cognition, dementia |
Research Division: | Biomedical and Clinical Sciences |
Research Group: | Clinical sciences |
Research Field: | Geriatrics and gerontology |
Objective Division: | Health |
Objective Group: | Specific population health (excl. Indigenous health) |
Objective Field: | Health related to ageing |
UTAS Author: | Callisaya, M (Dr Michele Callisaya) |
UTAS Author: | Srikanth, V (Dr Velandai Srikanth) |
ID Code: | 133262 |
Year Published: | 2019 |
Web of Science® Times Cited: | 1 |
Deposited By: | Menzies Institute for Medical Research |
Deposited On: | 2019-06-20 |
Last Modified: | 2020-08-14 |
Downloads: | 5 View Download Statistics |
Repository Staff Only: item control page